A Phase 1b, Randomized, Double-Blind, Placebo Controlled Study With an Open Label Extension to Evaluate the Safety and Tolerability of Omalizumab, A Humanized IgG1 Monoclonal Antibody in Patients With Lupus (STOP LUPUS)

Trial Profile

A Phase 1b, Randomized, Double-Blind, Placebo Controlled Study With an Open Label Extension to Evaluate the Safety and Tolerability of Omalizumab, A Humanized IgG1 Monoclonal Antibody in Patients With Lupus (STOP LUPUS)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Jan 2017

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Sjogren's syndrome; Systemic lupus erythematosus
  • Focus Adverse reactions
  • Acronyms STOP-LUPUS
  • Most Recent Events

    • 27 Oct 2016 Status changed from recruiting to active, no longer recruiting.
    • 17 Dec 2015 Planned End Date changed from 1 Jul 2030 to 1 Jul 2020, according to ClinicalTrials.gov record.
    • 14 Feb 2015 Planned End Date changed from 1 Jun 2016 to 1 Jul 2030 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top